NKTX

Equibles Rating blended score · not investment advice

Overall

Buy

Technical · trend & momentum Buy

◦ 50 / 200-day cross no cross

+ Price vs 200-day avg +41% above

+ Price vs 50-day avg +14% above

◦ RSI (14) 64 · neutral

+ MACD trend positive

◦ 52-week position 82% · mid-range

Sentiment · smart money Neutral

◦ Trend (MA cross) 50d $3 › 200d $2 — 50d above 200d

− Institutional flow 1 of 125 funds reported for Jun 30 · net -2 sh shares

− Insider flow Net -$4.8K over 90 days · 100% sells

+ Short interest 4.83% of float · ▼ -33.9% MoM · 6.4 days cover

◦ Volume signal Volume near normal

+ Institution breadth 125 holders — near 3-yr high, broad support

Fundamentals Strong

+ EPS growth +12% Y/Y

− Free cash flow $-89.9M

+ Balance sheet net cash $39.6M

Blended from price, positioning & fundamentals · daily-close · not investment advice.

Up next

Next earnings call

Aug 12, 2026 Est · unconfirmed · in 5 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 12, 2026

Technicals

trend & momentum for long-term holders Buy

0 · 3 · 3

50 / 200-day cross

no cross Neutral

Price vs 200-day avg

+41% above Bullish

Price vs 50-day avg

+14% above Bullish

RSI (14)

64 · neutral Neutral

MACD trend

positive Bullish

52-week position

82% · mid-range Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $3 › 200d $2 — 50d above 200d

Institutional flow Distributing

1 of 125 funds reported for Jun 30 · net -2 sh shares

Insider flow Distributing

Net -$4.8K over 90 days · 100% sells

Short interest Falling

4.83% of float · ▼ -33.9% MoM · 6.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

125 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $2 Now $3 · 82% 52-wk high $4

vs 200-day avg +41% vs 50-day avg +14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
NKTX Nkarta, Inc. this stock	$236.10M	+78.4%	—	—	4.8%
ONC BeOne Medicines Ltd.	$488.96B	+1.9%	+22179.2%	995.1	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$132.92B	+16.8%	+46.2%	31.1	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$69.33B	-15.7%	+20.8%	16.1	3.2%
ARGX Argenx SE	$57.87B	+9.0%	—	—	2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

125

% held: 80.4%
Reported: 1 of 125
Top holder: RA CAPITAL MANAGEMENT, L.…

Held Float

View

Held by Funds

Fund positions

104

View

Short & Settlement

Short Interest Falling

Shares short

3.5M

Days to cover: 6.4d
Change: -1.8M sh

View

Short Volume

Short vol %

48%

As of: Jul 7, 2026

Short Total

View

Fails to Deliver

FTD shares

669

Value: $1.9K
As of: Jun 5, 2026

View

Off-Exchange

Off-exchange %

50.5%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$4.8K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Revenue (FY)

Net income (FY): $-104.1M
EPS diluted: $-1.41

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Jun 30, 2026
This year: 8

View

Proposed Sales

Value

$23.8K

Shares: 3.4K
Filed: Jul 16, 2024

View

Earnings & Events

Earnings Calls

Last call

Jun 30, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
NKTX	+16.6%	+19.1%	+57.9%	+16.6%	+78.4%
SPY	+3.1%	-0.8%	+8.2%	+0.6%	+10.2%
vs SPY	+13.6%	+19.9%	+49.7%	+16.0%	+68.2%

Price & Indicators

Technicals

Versus peers

At a glance

Performance